CC
RYTM icon

Commodore Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Commodore Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-650,000
Closed -$34.1M – 38
2024
Q3 		$34.1M Sell
650,000
-575,000
-47% -$27.6M 2.13% 18
2024
Q2 		$50.3M Buy
1,225,000
+175,000
+17% +$6.99M 3.43% 11
2024
Q1 		$45.5M Sell
1,050,000
-500,000
-32% -$21.9M 3.04% 11
2023
Q4 		$71.3M Sell
1,550,000
-525,000
-25% -$16.6M 6.23% 5
2023
Q3 		$47.6M Buy
+2,075,000
New +$46.5M 5.56% 6

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commodore Capital's RYTM Position: Q4 2024 in Review

Commodore Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 650,000 shares — an estimated $34.1M sold.

Commodore Capital first reported a position in RYTM in Q3 2023 and held it in 5 quarters. The position peaked at $71.3M in Q4 2023. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Commodore Capital reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Commodore Capital sold 650,000 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $34.1M.
  • Commodore Capital first reported a position in Rhythm Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Commodore Capital's Rhythm Pharmaceuticals position peaked at $71.3M in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Commodore Capital's 13F filing for Q4 2024, filed 14 Feb 2025.